EUCTR2018-003219-23-GB进行中（未招募）1 期
CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease): A phase 3 randomised double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease - CHIEF-PD
niversity of Bristol0 个研究点目标入组 600 人开始时间: 2019年6月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a.Diagnosis of idiopathic Parkinson’s disease.
- •b.Modified Hoehn and Yahr stage 1-4 disease.
- •c.Have experienced a fall in the previous year.
- •d.Able to walk =10m without aids or assistance.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 125
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 475
排除标准
- •a.Previous ChEi use in 12 months prior to enrolment.
- •b.Hypersensitivity to rivastigmine
- •c.Dementia diagnosed according to Movement Disorder Society (MDS) criteria.
- •d.Inability to attend or comply with treatment or follow-up scheduling.
- •e.Non-English-speaking patients (cognitive tests performed in English).
- •f.Falling =4x per day.
- •g.Unwillingness to use an acceptable method of contraception for the duration of the trial if they are of childbearing potential.
研究者
相似试验
已完成
3 期
A trial of rivastigmine to prevent falls in Parkinson'sParkinson's DiseaseNervous System DiseasesISRCTN41639809niversity of Bristol600
进行中（未招募）
不适用
The effect of the cholinesterase inhibitor donepezil on organic and functional deficits related to growth hormone deficiency in old age.We plan to study healthy aging subjects.EUCTR2005-001315-22-ATudwig Boltzmann Gesellschaft80
已完成
2 期
Pyridostigmine: using a cholinesterase inhibitor to activate the cholinergic anti-inflammatory pathway in patients with CRPS-1pijn syndroomdystrophypost-traumatic dystrophyreflex sympathetic dystrophyNL-OMON33787Vrije Universiteit Medisch Centrum10
进行中（未招募）
不适用
Pyridostigmine: using a cholinesterase inhibitor to activate the cholinergic anti-inflammatory pathway in patients with CRPS-1 - Pyridostigmine trialPatients with CRPS-1.EUCTR2009-010758-36-NLVU University Medical Center10
已完成
3 期
CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)Parkinson DiseaseNCT04226248University of Bristol600